English
English Indonesia Türkçe Deutsch Español Português Pусский Français Italiano Nederlands Polski العربية ไทย Tiếng Việt 繁體中文 简体中文 日本語 한국어

#fdafasttrack search results

RetinalPhys's profile picture. Therapies and surgical treatment of the posterior segment
Retinal Physician
 @RetinalPhys
Oct 5, 2024

Priovant Therapeutics has begun a phase 3 trial evaluating brepocitinib as a uveitis treatment. Read more: ow.ly/IHeG50TCnrc #uveitis #retinalphysician #FDAfasttrack

RetinalPhys's tweet image. Priovant Therapeutics has begun a phase 3 trial evaluating brepocitinib as a uveitis treatment. Read more: ow.ly/IHeG50TCnrc #uveitis #retinalphysician #FDAfasttrack
0
1
2
0
159
MedTechNow_'s profile picture. Updates for anyone following, investing, or inquiring about the biotech/biopharma/MedTech industry. Not to be conflated with financial advise.
BiotechTechNow
 @MedTechNow_
Jun 30, 2023

#regulatory #news ~@genprex receives #FDAFastTrack for REQORSA® #immunogene rtherapy ~@BioMarin wins #FDAApproval for first #HemophiliaA #GeneTherapy ~FDA Approves @ARUPLabs' AAV5 DetectCDx™, first-companion diagnostic #Immunoassay for #GeneTherapy

MedTechNow_'s tweet image. #regulatory #news ~@genprex receives #FDAFastTrack for REQORSA® #immunogene rtherapy ~@BioMarin wins #FDAApproval for first #HemophiliaA #GeneTherapy ~FDA Approves @ARUPLabs' AAV5 DetectCDx™, first-companion diagnostic #Immunoassay for #GeneTherapy
0
1
1
0
255
OTRADIBio's profile picture. Oregon's only bioscience-focused incubator, providing labs, offices, shared equipment and entrepreneurial mentoring for bio and digital health startups.
OBI
 @OTRADIBio
Jul 1

🚨 Final Session Alert! 🚨 Join us Tue, July 15 | 12–1 PM (PDT) on Zoom for FDA Programs to Expedite Drug Development with Elizabeth Gordon, sponsored by RAIN Catalysts. Free to attend. Register now: zurl.co/nR7ku #FDAFastTrack #DrugDevelopment #BiotechEvents

OTRADIBio's tweet image. 🚨 Final Session Alert! 🚨 Join us Tue, July 15 | 12–1 PM (PDT) on Zoom for FDA Programs to Expedite Drug Development with Elizabeth Gordon, sponsored by RAIN Catalysts. Free to attend. Register now: zurl.co/nR7ku #FDAFastTrack #DrugDevelopment #BiotechEvents
0
0
0
0
7
NTMinfo's profile picture. #NTMir Non-profit organization dedicated to patient support, medical education & research for people with nontuberculous mycobacterial lung disease (#NTM).
NTM Info & Research
 @NTMinfo
May 9, 2024

Pulmonary NTM infection is recognized as a major global health concern due to its rising prevalence worldwide, association with shortened life span and significant impact on patients’ daily living. #MannKind #FDAFastTrack #NTMLungDisease Learn more at bit.ly/3wpEGxh

NTMinfo's tweet image. Pulmonary NTM infection is recognized as a major global health concern due to its rising prevalence worldwide, association with shortened life span and significant impact on patients’ daily living. #MannKind #FDAFastTrack #NTMLungDisease Learn more at bit.ly/3wpEGxh
0
1
2
1
94
MedTechNow_'s profile picture. Updates for anyone following, investing, or inquiring about the biotech/biopharma/MedTech industry. Not to be conflated with financial advise.
BiotechTechNow
 @MedTechNow_
Oct 3, 2023

#regulatory #news ~@AvengeBio receives #FDAFastTrack for #CellTherapy leveraging its #Immunotherapy platform @Calliditas1 files with @MHRAgovuk for Kinpeygo in IgA #nephropathy ~@AlzamendNeuro receives FDA “Study May Proceed” notification for study in #BipolarDisorder

MedTechNow_'s tweet image. #regulatory #news ~@AvengeBio receives #FDAFastTrack for #CellTherapy leveraging its #Immunotherapy platform @Calliditas1 files with @MHRAgovuk for Kinpeygo in IgA #nephropathy ~@AlzamendNeuro receives FDA “Study May Proceed” notification for study in #BipolarDisorder
0
0
0
0
123
biopointinc's profile picture. Recently ranked 49th fastest growing private companies in the United States by Inc.5000 #BioPoint is a US based life sciences workforce solutions provider.
BioPoint Inc.
 @biopointinc
Jun 18

The FDA, under Commissioner Martin Makary, is piloting a voucher program that could expedite drug reviews to one or two months. This fast-track approval process is contingent on the drug meeting specific requirements. biopharmadive.com/news/FDA-natio… #fdaapproval #fdafasttrack #fda

biopointinc's tweet card. A new pilot program announced by FDA Commissioner Martin Makary would award vouchers that could cut drug reviews to one or two months — but only for products that meet a special criteria.
FDA to speed reviews for drugs supporting ‘national interests’
Source: biopharmadive.com
0
0
0
0
38
MedTechNow_'s profile picture. Updates for anyone following, investing, or inquiring about the biotech/biopharma/MedTech industry. Not to be conflated with financial advise.
BiotechTechNow
 @MedTechNow_
Feb 16, 2024

#regulatory roundup ~@Diamyd receives #FDAFastTrack designation for Diamyd® ~FDA approves @SamsungUS’s #sleepapnea feature on #Galaxywatch, phone ~FDA grants clearance to @nanox_vision #AI #software to assess early signs of #fattyliver

MedTechNow_'s tweet image. #regulatory roundup ~@Diamyd receives #FDAFastTrack designation for Diamyd® ~FDA approves @SamsungUS’s #sleepapnea feature on #Galaxywatch, phone ~FDA grants clearance to @nanox_vision #AI #software to assess early signs of #fattyliver
0
1
3
0
270
NSPharmaInc's profile picture. Dedicated to improving patient outcomes in #Duchenne muscular dystrophy, eosinophilic granulomatosis with polyangiitis (#EGPA) and other #rarediseases.
NS Pharma
 @NSPharmaInc
Sep 9

We’re excited to share that the FDA has granted Fast Track designation to NS-229 for Eosinophilic Granulomatosis with Polyangiitis (#EGPA), a rare autoimmune disease! Read the full announcement: ow.ly/h95w50WTUFl #RareDiseases #FDAFastTrack #PharmaInnovation

NSPharmaInc's tweet image. We’re excited to share that the FDA has granted Fast Track designation to NS-229 for Eosinophilic Granulomatosis with Polyangiitis (#EGPA), a rare autoimmune disease! Read the full announcement: ow.ly/h95w50WTUFl #RareDiseases #FDAFastTrack #PharmaInnovation
0
0
1
0
113
JIsaias_Noah's profile picture. Technology Edit Keeping @NoahBreaking readers up-to-date with the latest gadgets and software. Exploring the broader implications of technology. 🖥️🚀
Jaimie Isaias
 @JIsaias_Noah
Feb 22, 2024

Artiva Biotherapeutics' lupus treatment receives FDA Fast Track designation noah-news.com/gb/en/health/2… #lupusnephritis #FDAFastTrack #immunotherapy

0
0
0
0
14
kalkineau's profile picture. Stay ahead with Kalkine – real-time market news, ASX insights & financial updates that matter. Kalkine, market insights, ASX news, financial updates
Kalkine Media Australia
 @kalkineau
Apr 16, 2024

Telix Pharmaceuticals has announced a significant milestone in its development of a new glioma imaging product, TLX101-CDx. #TelixPharmaceuticals #FDAFastTrack #GliomaImaging #TLX101CDx #MedicalInnovation #CancerDiagnosis #BrainTumor #HealthcareNews zurl.co/OhsD

0
0
0
0
45
MAIABiotech's profile picture. MAIA Biotech is a targeted therapy, immuno-oncology company focused on the development and commercialization of first-in-class drugs. $MAIA
MAIA Biotechnology, Inc.
 @MAIABiotech
Aug 12

FDA grants Fast Track designation to MAIA’s ateganosine for #NSCLC. The telomere-targeting therapy showed partial responses in phase 2 THIO-101 trial with cemiplimab in patients with advanced NSCLC. Read more via @CancerTherAdvsr: bit.ly/4oMz1HY #Oncology #FDAFastTrack

0
1
17
1
1K
PharmaNowGlobal's profile picture. Pharma Now is one of the leading monthly B2B magazines publishing premium content relevant to the pharma industry.
Pharma Now
 @PharmaNowGlobal
Apr 2

FDA fast-tracks Empaveli for kidney disease, accelerating its development to address unmet patient needs in renal care. @ApellisPharma 📖 Read more: pharmanow.live/latest-news/fd… #Empaveli #FDAFastTrack #KidneyDisease #RenalCare #PharmaNews #HealthcareInnovation

PharmaNowGlobal's tweet card. Apellis’ EMPAVELI® for rare kidney diseases gets FDA Priority Review; intense Phase 3 results support approval bid.
FDA Fast-Tracks EMPAVELI® Kidney Drug
Source: pharmanow.live
0
0
0
0
23
EnsysceBio's profile picture. Ensysce, a clinical-stage biotech, developing a new class of drugs to provide patients & prescribers safer options designed to reduce abuse & prevent overdose.
Ensysce Biosciences
 @EnsysceBio
Feb 20, 2024

Ensysce has earned both “Fast Track” and “Breakthrough Therapy Designation” (BTD)  from the FDA!  What do they mean? Check out this piece on the #FDA site about BTD. #fdafasttrack #fdabtd #bioscience #opioidpharma fda.gov/regulatory-inf…

EnsysceBio's tweet card. The Food and Drug Administration Safety and Innovation Act (FDASIA) includes a provision that allows sponsors to request that their drug be designated as a Breakthrough Therapy. 
Fact Sheet: Breakthrough Therapies
Source: fda.gov
1
1
0
1
210
EnsysceBio's profile picture. Ensysce, a clinical-stage biotech, developing a new class of drugs to provide patients & prescribers safer options designed to reduce abuse & prevent overdose.
Ensysce Biosciences
 @EnsysceBio
Feb 20, 2023

Did you know that Ensysce has earned “Fast Track” designation from the FDA?  What does that mean? Check out this piece on the #FDA site. fda.gov/patients/fast-… #fdafasttrack #bioscience

0
0
1
0
152
CERo_bio's profile picture. At CERo, we are expanding the armamentarium of engineered cell therapies to create a whole new class of innovative medicines for oncology.
CERo Therapeutics, Inc.
@CERo_bio
Sep 16

Check out this article from Rare Cancer News on CER-1236, #CeroTherapeutics’ lead therapy for #AML, receiving #FDAFastTrack designation. CER-1236 uses CER T-cells to kill #cancercells & enhance the immune response. Full article: bit.ly/4pmOJtF $CERO #ClinicalTrials

CERo_bio's tweet card. The FDA granted fast track designation to CER-1236, an experimental cell therapy that Cero Therapeutics is developing as an AML treatment.
Cell therapy CER-1236 put on FDA fast track as AML treatment
Source: rarecancernews.com
0
0
6
0
100
NSPharmaInc's profile picture. Dedicated to improving patient outcomes in #Duchenne muscular dystrophy, eosinophilic granulomatosis with polyangiitis (#EGPA) and other #rarediseases.
NS Pharma
 @NSPharmaInc
Sep 9

We’re excited to share that the FDA has granted Fast Track designation to NS-229 for Eosinophilic Granulomatosis with Polyangiitis (#EGPA), a rare autoimmune disease! Read the full announcement: ow.ly/h95w50WTUFl #RareDiseases #FDAFastTrack #PharmaInnovation

NSPharmaInc's tweet image. We’re excited to share that the FDA has granted Fast Track designation to NS-229 for Eosinophilic Granulomatosis with Polyangiitis (#EGPA), a rare autoimmune disease! Read the full announcement: ow.ly/h95w50WTUFl #RareDiseases #FDAFastTrack #PharmaInnovation
0
0
1
0
113
MAIABiotech's profile picture. MAIA Biotech is a targeted therapy, immuno-oncology company focused on the development and commercialization of first-in-class drugs. $MAIA
MAIA Biotechnology, Inc.
 @MAIABiotech
Aug 12

FDA grants Fast Track designation to MAIA’s ateganosine for #NSCLC. The telomere-targeting therapy showed partial responses in phase 2 THIO-101 trial with cemiplimab in patients with advanced NSCLC. Read more via @CancerTherAdvsr: bit.ly/4oMz1HY #Oncology #FDAFastTrack

0
1
17
1
1K
No results for "#fdafasttrack"
EnsysceBio's profile picture. Ensysce, a clinical-stage biotech, developing a new class of drugs to provide patients & prescribers safer options designed to reduce abuse & prevent overdose.
Ensysce Biosciences
 @EnsysceBio
Dec 27, 2022

What does it mean-Ensysce’s PF614 with TAAPTM technology has earned FDA's “Fast Track” designation? It's designed to accelerate the process toward commercialization of select breakthrough therapies. en.wikipedia.org/wiki/Fast_trac… #fdafasttrack #bioscience #opioidpharma #pharmafasttrack

EnsysceBio's tweet image. What does it mean-Ensysce’s PF614 with TAAPTM technology has earned FDA's “Fast Track” designation? It's designed to accelerate the process toward commercialization of select breakthrough therapies. en.wikipedia.org/wiki/Fast_trac… #fdafasttrack #bioscience #opioidpharma #pharmafasttrack
1
0
2
0
290
EnsysceBio's profile picture. Ensysce, a clinical-stage biotech, developing a new class of drugs to provide patients & prescribers safer options designed to reduce abuse & prevent overdose.
Ensysce Biosciences
 @EnsysceBio
Sep 13, 2022

Did you know that Ensysce’s PF614 with TAAP technology has earned “Fast Track” designation from the FDA? What does that mean? Check out this piece on the #FDA site about the process. fda.gov/patients/fast-… #fdafasttrack #bioscience #opioidpharma

EnsysceBio's tweet image. Did you know that Ensysce’s PF614 with TAAP technology has earned “Fast Track” designation from the FDA? What does that mean? Check out this piece on the #FDA site about the process. fda.gov/patients/fast-… #fdafasttrack #bioscience #opioidpharma
0
1
2
0
0
EnsysceBio's profile picture. Ensysce, a clinical-stage biotech, developing a new class of drugs to provide patients & prescribers safer options designed to reduce abuse & prevent overdose.
Ensysce Biosciences
 @EnsysceBio
Oct 5, 2022

Ensysce in the NEWS: the latest release about the initiation of a 2nd human abuse potential study on PF614 vs immediate release oxycodone & relative potential for drug liking at equivalent drug dosages. ir.ensysce.com/news/press-rel… #fdafasttrack #biosciences #stopprescriptionabuse

EnsysceBio's tweet image. Ensysce in the NEWS: the latest release about the initiation of a 2nd human abuse potential study on PF614 vs immediate release oxycodone & relative potential for drug liking at equivalent drug dosages. ir.ensysce.com/news/press-rel… #fdafasttrack #biosciences #stopprescriptionabuse
0
0
1
0
0
EnsysceBio's profile picture. Ensysce, a clinical-stage biotech, developing a new class of drugs to provide patients & prescribers safer options designed to reduce abuse & prevent overdose.
Ensysce Biosciences
 @EnsysceBio
Dec 6, 2022

UPDATE: encouraging feedback & guidance from FDA for the Clinical Development Pathway for PF614, suggesting Ensysce’s approach appears reasonable to support a new drug application for an acute pain indication ir.ensysce.com/news/press-rel… #fdaguidance #fdafasttrack #clinicaltrials

EnsysceBio's tweet image. UPDATE: encouraging feedback & guidance from FDA for the Clinical Development Pathway for PF614, suggesting Ensysce’s approach appears reasonable to support a new drug application for an acute pain indication ir.ensysce.com/news/press-rel… #fdaguidance #fdafasttrack #clinicaltrials
0
1
4
0
0
EnsysceBio's profile picture. Ensysce, a clinical-stage biotech, developing a new class of drugs to provide patients & prescribers safer options designed to reduce abuse & prevent overdose.
Ensysce Biosciences
 @EnsysceBio
Nov 16, 2022

What does it mean that Ensysce’s PF614 with TAAP technology has earned “Fast Track” designation? Here’s how Wikipedia described the FDA’s “Fast Track” - accelerating the process of select therapies. en.wikipedia.org/wiki/Fast_trac… #fdafasttrack #bioscience #opioidpharma #pharmafasttrack

EnsysceBio's tweet image. What does it mean that Ensysce’s PF614 with TAAP technology has earned “Fast Track” designation? Here’s how Wikipedia described the FDA’s “Fast Track” - accelerating the process of select therapies. en.wikipedia.org/wiki/Fast_trac… #fdafasttrack #bioscience #opioidpharma #pharmafasttrack
0
3
7
0
0
EnsysceBio's profile picture. Ensysce, a clinical-stage biotech, developing a new class of drugs to provide patients & prescribers safer options designed to reduce abuse & prevent overdose.
Ensysce Biosciences
 @EnsysceBio
Oct 18, 2022

Status update: the head of the Food and Drug Administration says a government review of prescription opioid medications, including their risks & contribution to the U.S. overdose epidemic, is still underway. usnews.com/news/health-ne… #nextgenpharma #fdafasttrack #prescriptionabuse

EnsysceBio's tweet image. Status update: the head of the Food and Drug Administration says a government review of prescription opioid medications, including their risks & contribution to the U.S. overdose epidemic, is still underway. usnews.com/news/health-ne… #nextgenpharma #fdafasttrack #prescriptionabuse
1
1
3
0
0
EnsysceBio's profile picture. Ensysce, a clinical-stage biotech, developing a new class of drugs to provide patients & prescribers safer options designed to reduce abuse & prevent overdose.
Ensysce Biosciences
 @EnsysceBio
Oct 20, 2022

The FDA’s “Fast Track” program accelerates the process toward commercialization of select therapies. Did you know that Ensysce’s PF614 with TAAP TM technology has earned “Fast Track” designation? fda.gov/patients/fast-… #fdafasttrack #bioscience #opioidpharma #pharmafasttrack

EnsysceBio's tweet image. The FDA’s “Fast Track” program accelerates the process toward commercialization of select therapies. Did you know that Ensysce’s PF614 with TAAP TM technology has earned “Fast Track” designation? fda.gov/patients/fast-… #fdafasttrack #bioscience #opioidpharma #pharmafasttrack
0
3
8
0
0
NTMinfo's profile picture. #NTMir Non-profit organization dedicated to patient support, medical education & research for people with nontuberculous mycobacterial lung disease (#NTM).
NTM Info & Research
 @NTMinfo
May 9, 2024

Pulmonary NTM infection is recognized as a major global health concern due to its rising prevalence worldwide, association with shortened life span and significant impact on patients’ daily living. #MannKind #FDAFastTrack #NTMLungDisease Learn more at bit.ly/3wpEGxh

NTMinfo's tweet image. Pulmonary NTM infection is recognized as a major global health concern due to its rising prevalence worldwide, association with shortened life span and significant impact on patients’ daily living. #MannKind #FDAFastTrack #NTMLungDisease Learn more at bit.ly/3wpEGxh
0
1
2
1
94
MedTechNow_'s profile picture. Updates for anyone following, investing, or inquiring about the biotech/biopharma/MedTech industry. Not to be conflated with financial advise.
BiotechTechNow
 @MedTechNow_
Feb 16, 2024

#regulatory roundup ~@Diamyd receives #FDAFastTrack designation for Diamyd® ~FDA approves @SamsungUS’s #sleepapnea feature on #Galaxywatch, phone ~FDA grants clearance to @nanox_vision #AI #software to assess early signs of #fattyliver

MedTechNow_'s tweet image. #regulatory roundup ~@Diamyd receives #FDAFastTrack designation for Diamyd® ~FDA approves @SamsungUS’s #sleepapnea feature on #Galaxywatch, phone ~FDA grants clearance to @nanox_vision #AI #software to assess early signs of #fattyliver
0
1
3
0
270
EnsysceBio's profile picture. Ensysce, a clinical-stage biotech, developing a new class of drugs to provide patients & prescribers safer options designed to reduce abuse & prevent overdose.
Ensysce Biosciences
 @EnsysceBio
Apr 26, 2022

Did you know that Ensysce’s science has earned “Fast Track” designation from the FDA? What does that mean? Check out this piece on the #FDA site about the process. fda.gov/patients/fast-… #fdafasttrack #bioscience #opioidpharma

EnsysceBio's tweet image. Did you know that Ensysce’s science has earned “Fast Track” designation from the FDA? What does that mean? Check out this piece on the #FDA site about the process. fda.gov/patients/fast-… #fdafasttrack #bioscience #opioidpharma
16
0
3
0
0
freund_paula's profile picture. I Have ALS/Lou Gehrig's Disease. I Fight Every day and Push Forward. I may have ALS---But I am NOT giving up or giving in to this Monster !! #ScrewYouALS
Paula F Freund
 @freund_paula
Nov 4, 2019

@FDACommissioner @POTUS @realDonaldTrump ALS Therapies need approval ASAP! #Nurown#Tregs#CuAtsm #FDAapproval #FDAfasttrack #Executiveorder We don't have years to wait!!

freund_paula's tweet image. @FDACommissioner @POTUS @realDonaldTrump ALS Therapies need approval ASAP! #Nurown#Tregs#CuAtsm #FDAapproval #FDAfasttrack #Executiveorder We don't have years to wait!!
0
3
1
0
0
freund_paula's profile picture. I Have ALS/Lou Gehrig's Disease. I Fight Every day and Push Forward. I may have ALS---But I am NOT giving up or giving in to this Monster !! #ScrewYouALS
Paula F Freund
 @freund_paula
Dec 16, 2019

@SteveHahnMD @FDACommissioner @US_FDA @POTUS @FLOTUS @JujuChangABC Every year my siblings sit in the same spots on a sofa and take a picture. I want to continue to be in the picture too !! #Nurown #FDAApproval #FDAFasttrack #EndALS #Hearourplea #alstherapy

freund_paula's tweet image. @SteveHahnMD @FDACommissioner @US_FDA @POTUS @FLOTUS @JujuChangABC Every year my siblings sit in the same spots on a sofa and take a picture. I want to continue to be in the picture too !! #Nurown #FDAApproval #FDAFasttrack #EndALS #Hearourplea #alstherapy
1
5
9
0
0
MedTechNow_'s profile picture. Updates for anyone following, investing, or inquiring about the biotech/biopharma/MedTech industry. Not to be conflated with financial advise.
BiotechTechNow
 @MedTechNow_
May 22, 2023

more #regulatory wins ~@SangamoTx receives #FDAFastTrack designation for treatment of #FabryDisease ~@boehringerus Ingelheim receives #FDA approval for Cyltezo ® Pen ~@Hologic wins FDA clearance for #COVID-#flu-#RSV assay

MedTechNow_'s tweet image. more #regulatory wins ~@SangamoTx receives #FDAFastTrack designation for treatment of #FabryDisease ~@boehringerus Ingelheim receives #FDA approval for Cyltezo ® Pen ~@Hologic wins FDA clearance for #COVID-#flu-#RSV assay
0
0
0
0
75
MedTechNow_'s profile picture. Updates for anyone following, investing, or inquiring about the biotech/biopharma/MedTech industry. Not to be conflated with financial advise.
BiotechTechNow
 @MedTechNow_
Oct 3, 2023

#regulatory #news ~@AvengeBio receives #FDAFastTrack for #CellTherapy leveraging its #Immunotherapy platform @Calliditas1 files with @MHRAgovuk for Kinpeygo in IgA #nephropathy ~@AlzamendNeuro receives FDA “Study May Proceed” notification for study in #BipolarDisorder

MedTechNow_'s tweet image. #regulatory #news ~@AvengeBio receives #FDAFastTrack for #CellTherapy leveraging its #Immunotherapy platform @Calliditas1 files with @MHRAgovuk for Kinpeygo in IgA #nephropathy ~@AlzamendNeuro receives FDA “Study May Proceed” notification for study in #BipolarDisorder
0
0
0
0
123
freund_paula's profile picture. I Have ALS/Lou Gehrig's Disease. I Fight Every day and Push Forward. I may have ALS---But I am NOT giving up or giving in to this Monster !! #ScrewYouALS
Paula F Freund
 @freund_paula
Dec 16, 2019

@FDACommissioner @US_FDA @SteveHahnMD @realDonaldTrump @HHSGov @USCongress Hurry up and Save Lives ! NUROWN APPROVAL #NUROWN #FDAFASTTRACK #FDAAPPROVAL #ENDALS

1
2
3
0
0
MedTechNow_'s profile picture. Updates for anyone following, investing, or inquiring about the biotech/biopharma/MedTech industry. Not to be conflated with financial advise.
BiotechTechNow
 @MedTechNow_
Nov 1, 2022

#regulatory wins ~@Dyne_tx receives #FDAFastTrack for #DuchenneMuscularDystrophy treatment ~@antengene receives #FDA #IND clearance for #SmallMolecule trial ~@AlzamendNeuro receives FDA “Study May Proceed” letter for #Immunotherapy #vaccine for mild-moderate #Dementia

MedTechNow_'s tweet image. #regulatory wins ~@Dyne_tx receives #FDAFastTrack for #DuchenneMuscularDystrophy treatment ~@antengene receives #FDA #IND clearance for #SmallMolecule trial ~@AlzamendNeuro receives FDA “Study May Proceed” letter for #Immunotherapy #vaccine for mild-moderate #Dementia
0
1
1
0
0
freund_paula's profile picture. I Have ALS/Lou Gehrig's Disease. I Fight Every day and Push Forward. I may have ALS---But I am NOT giving up or giving in to this Monster !! #ScrewYouALS
Paula F Freund
 @freund_paula
Mar 23, 2020

@SteveFDA @realDonaldTrump @als_now @stevens_nation Pandemic.....Yes.......BUT...... LISTEN ALS loses 6000 lives EVERY Year !! 30,000 ALS Patients currently dying ALS kills an American every 90 min. Wake Up FDA !! We Matter Too !! #Nurown #FDAApproval #FDAFasttrack

freund_paula's tweet image. @SteveFDA @realDonaldTrump @als_now @stevens_nation Pandemic.....Yes.......BUT...... LISTEN ALS loses 6000 lives EVERY Year !! 30,000 ALS Patients currently dying ALS kills an American every 90 min. Wake Up FDA !! We Matter Too !! #Nurown #FDAApproval #FDAFasttrack
0
6
4
0
0

Something went wrong.


Something went wrong.


United States Trends